Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06081959 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Mar 31, 2026 to Dec 31, 2026v6
  2. Lead sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. to Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.v5
  3. Lead sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.v4
  4. Lead sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. to Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.v3
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Nov 30, 2023 to Oct 31, 2023 · Secondary endpoints revised (7) · 1 morev2 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 30, 2023 to Oct 31, 2023
    • Secondary endpoints revised (7)
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer.
Trial Details
NCT Number NCT06081959
Lead Sponsor Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions Metastatic Breast Cancer
Enrollment 376 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov